Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

PURPOSE: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly-diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Omuro, Antonio, Beal, Kathryn, Gutin, Philip, Karimi, Sasan, Correa, Denise D., Kaley, Thomas J., DeAngelis, Lisa M., Chan, Timothy A., Gavrilovic, Igor T., Nolan, Craig, Hormigo, Adilia, Lassman, Andrew B., Mellinghoff, Ingo, Grommes, Christian, Reiner, Anne S., Panageas, Katherine S., Baser, Raymond E., Tabar, Viviane, Pentsova, Elena, Sanchez, Juan, Barradas-Panchal, Renata, Zhang, Jianan, Faivre, Geraldine, Brennan, Cameron W., Abrey, Lauren E., Huse, Jason T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4523080/
https://ncbi.nlm.nih.gov/pubmed/25107913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0822
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados